Charles Schwab
PYXS icon

Charles Schwab’s Pyxis Oncology PYXS Stock Holding History

Charles Schwab’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-115,237
Closed -$113K – 3556
2025
Q1 		$113K Sell
115,237
-14,524
-11% -$19.4K ﹤0.01% 3327
2024
Q4 		$202K Hold
129,761
– – ﹤0.01% 3326
2024
Q3 		$476K Hold
129,761
– – ﹤0.01% 3173
2024
Q2 		$430K Buy
129,761
+115,237
+793% +$484K ﹤0.01% 3258
2024
Q1 		$61.9K Buy
+14,524
New +$61.1K ﹤0.01% 3348
2023
Q2 		– Sell
-17,739
Closed -$71.1K – 3667
2023
Q1 		$71.1K Hold
17,739
– – ﹤0.01% 3293
2022
Q4 		$23.8K Hold
17,739
– – ﹤0.01% 3480
2022
Q3 		$35K Buy
+17,739
New +$46.3K ﹤0.01% 3410
2022
Q2 		– Sell
-23,094
Closed -$94K – 3625
2022
Q1 		$94K Hold
23,094
– – ﹤0.01% 3422
2021
Q4 		$254K Buy
+23,094
New +$264K ﹤0.01% 3317

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab's PYXS Position: Q2 2025 in Review

Charles Schwab sold out of Pyxis Oncology (PYXS) in Q2 2025, closing a stake of 115,237 shares — an estimated $113K sold.

Charles Schwab first reported a position in PYXS in Q4 2021 and held it in 10 quarters. The position peaked at $476K in Q3 2024. 74 funds tracked by Wall St. Rank hold PYXS as of Q2 2025.

  • Charles Schwab reported no remaining Pyxis Oncology position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 115,237 Pyxis Oncology shares in Q2 2025, an estimated $113K.
  • Charles Schwab first reported a position in Pyxis Oncology in Q4 2021 and held it in 10 quarters.
  • Charles Schwab's Pyxis Oncology position peaked at $476K in Q3 2024.
  • 74 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.